Table 2.

Overview of the four included in vitro investigations.

Author, Year, Location [Ref]	Aims	Results
Graillon, 2015, France [41]	Activity of octreotide, everolimus, BKM-120 and BEZ-235 (new Pi3K/Akt/mTOR inhibitors), and a combined treatment (octreotide plus everolimus) on signaling pathways, cell proliferation, and cell cycle proteins in meningioma primary cells.	n = 23 patients. SSTR2 mRNA expression in all tested cells. Octreotide decreased cell viability. Enhanced decrease with a combined treatment of octreotide and everolimus.
Graillon, 2017a, France [42]	Comparison of pasireotide and octreotide, both alone and in combination with everolimus, on meningioma primary cell cultures.	Pasireotide induces a higher reduction in cell viability and stronger inhibitory effect on cell proliferation than octreotide, both alone and in combination with everolimus.
Graillon, 2017b, France [43]	Evaluate the effect of octreotide on meningioma primary cell cultures.	n = 80 meningioma primary cell cultures. Octreotide significantly decreased cell proliferation in the majority of meningiomas but did not induce apoptosis. Improved octreotide effect on cell viability if elevated level of SSTR2.
Koper, 1992, Netherlands [44]	Effects of somatostatin and octreotide on the growth of cultured human meningioma cells.	Significant stimulation of growth.